Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1007 in Acute Lower GI GVHD
NCT02245412Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2014
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of olendalizumab in Acute Graft-Versus-Host Disease (aGvHD) (3 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Overall Acute Graft-Versus-Host Disease (GVHD) Response Rate At Day 28. Started Nov 2014; status: terminated.
02
Drugs
olendalizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02245412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245412.